Sunitinib in advanced alveolar soft part sarcoma: Evidence of a direct antitumor effect

Annals of Oncology

Volumn 22, Issue 7, 2011, Pages 1682-1690

  Stacchiotti, S ^a   Negri, T ^a   Zaffaroni, N ^a   Palassini, E ^a   Morosi, C ^a   Brich, S ^a   Conca, E ^a   Bozzi, F ^a   Cassinelli, G ^a   Gronchi, A ^a   Casali, P G ^a   Pilotti, S ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

ASPS; Sarcoma; Sunitinib; Tyrosine kinase inhibitors

Indexed keywords

BEVACIZUMAB; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN RET; SCATTER FACTOR RECEPTOR; SUNITINIB; VASCULOTROPIN RECEPTOR 2;

ADULT; ADVANCED CANCER; ALVEOLAR SOFT PART SARCOMA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; BONE METASTASIS; BRAIN METASTASIS; CANCER GROWTH; CANCER SURVIVAL; CELL CULTURE; CELL GROWTH; CHROMOSOME ANALYSIS; CLINICAL ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG RESPONSE; FATIGUE; FEMALE; FLOW CYTOMETRY; GENE MUTATION; HUMAN; HUMAN CELL; HYPERTENSION; HYPOTHYROIDISM; IMMUNOFLUORESCENCE; LIVER METASTASIS; LIVER TOXICITY; LUNG METASTASIS; MALE; METASTASIS POTENTIAL; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SOFT TISSUE METASTASIS; THROMBOCYTOPENIA; TREATMENT DURATION; TUMOR LOCALIZATION;

EID: 79958717044     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq644     Document Type: Article

References (39)

1. Portera CA Jr, Ho V, Patel SR et al. Alveolar soft part sarcoma: clinical course and patterns of metastasis in 70 patients treated at a single institution. Cancer 2001; 91: 585-591.
2. Lazar AJ, Das P, Tuvin D et al. Angiogenesis-promoting gene patterns in alveolar soft part sarcoma. Clin Cancer Res 2007; 13: 7314-7321.
3. Lieberman PH, Brennan MF, Kimmel M et al. Alveolar soft-part sarcoma. A clinico-pathologic study of half a century. Cancer 1989; 63: 1-13.
4. Pennacchioli E, Fiore M, Collini P et al. Alveolar soft part sarcoma: clinical presentation, treatment, and outcome in a series of 33 patients at a single institution. Ann Surg Oncol 2010; in press.
5. Ogose A, Yazawa Y, Ueda T et al. Alveolar soft part sarcoma in Japan: multiinstitutional study of 57 patients from the Japanese Musculoskeletal Oncology Group. Oncology 2003; 65: 7-13.
6. Reichardt P, Lindner T, Pink D et al. Chemotherapy in alveolar soft part sarcomas. What do we know? Eur J Cancer 2003; 39: 1511-1516.
7. Landanyi M, Lui MY, Antonescu CR et al. The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25. Oncogene 2001; 20: 48-57.
8. Goldberg J, Demetri GD, Choy E et al. Preliminary results from a phase II study of ARQ197 in patients with microphthalmia transcription factor family (MiT)-associated tumors. J Clin Oncol 2009; 27: 536s (suppl: Abstr 10502).
9. Stockwin LH, Vistica DT, Kenney S et al. Gene expression profiling of alveolar soft-part sarcoma (ASPS). BMC Cancer 2009; 9: 22.
10. Lazar AJ, Lahat G, Myers SE et al. Validation of potential therapeutic targets in alveolar soft part sarcoma: an immunohistochemical study utilizing tissue microarray. Histopathology 2009; 55: 750-755.
11. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005; 23: 1011-1027.
12. Decaussin M, Sartelet H, Robert C et al. Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGF-R1-Flt1 and VEGF-R2-Flk1/ KDR) in non-small cell lung carcinomas (NSCLCs): correlation with angiogenesis and survival. J Pathol 1999; 188: 369-377.
13. Morelli MP, Brown AM, Pitts TM et al. Targeting vascular endothelial growth factor receptor-1 and -3 with cediranib (AZD2171): effects on migration and invasion of gastrointestinal cancer cell lines. Mol Cancer Ther 2009; 8: 2546-2558.
14. Tamborini E, Casieri P, Miselli F et al. Analysis of potential receptor tyrosine kinase targets in intimal and mural sarcomas. J Pathol 2007; 212: 227-235.
15. Tamborini E, Virdis E, Negri T et al. Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordoma. Neuro Oncol 2010; 12: 776-789.
16. Stacchiotti S, Tamborini E, Marrari A et al. Response to sunitinib malate in advanced alveolar soft part sarcoma. Clin Cancer Res 2009; 15: 1096-1104.
17. Van Belle E, Witzenbichler B, Chen D et al. Potentiated angiogenic effect of scatter factor/hepatocyte growth factor via induction of vascular endothelial growth factor: the case for paracrine amplification of angiogenesis. Circulation 1998; 97: 381-390.
18. Tufro A, Teichman J, Banu N et al. Crosstalk between VEGF-A/VEGFR2 and GDNF/RET signaling pathways. Biochem Biophys Res Commun 2007; 358: 410-416.
19. Popsueva A, Poteryaev D, Arighi E et al. GDNF promotes tubulogenesis of GFRalpha1-expressing MDCK cells by Src-mediated phosphorylation of Met receptor tyrosine kinase. J Cell Biol 2003; 161: 119-129.
20. Bisogno G, Rosolen A, Carli M. Interferon alpha for alveolar soft part sarcoma. Pediatr Blood Cancer 2005; 44: 687-688.
21. Roozendaal KJ, de Valk B, ten Velden JJ et al. Alveolar soft-part sarcoma responding to interferon alpha-2b. Br J Cancer 2003; 89: 243-245.
22. Kuriyama K, Todo S, Hibi S et al. Alveolar soft part sarcoma with lung metastases. Response to interferon alpha-2a? Med Pediatr Oncol 2001; 37: 482-483.
23. Azizi AA, Haberler C, Czech T et al. Vascular-endothelial-growth-factor (VEGF) expression and possible response to angiogenesis inhibitor bevacizumab in metastatic alveolar soft part sarcoma. Lancet Oncol 2006; 7: 521-523.
24. George S, Merriam P, Maki RG et al. Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol 2009; 27: 3154-3160.
25. Gardner K, Judson I, Leahy M et al. Activity of cediranib, a highly potent and selective VEGF signaling inhibitor, in alveolar soft part sarcoma. J Clin Oncol 2009; 27: 541s (suppl: Abstr 10523).
26. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer Institute of the United States, National Cancer Insitute of Canada. J Natl Cancer Inst 2000; 92: 205-206.
27. Young H, Baum R, Cremerius U et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999; 35: 1773-1782.
28. Negri T, Virdis E, Brich S et al. Functional mapping of receptor tyrosine kinases in myxoid liposarcoma. Clin Cancer Res 2010; 16: 3581-3593.
29. Negri T, Bozzi F, Conca E et al. Oncogenic and ligand-dependent activation of KIT/PDGFRA in surgical samples of imatinib-treated gastrointestinal stromal tumours (GISTs). J Pathol 2009; 217: 103-112.
30. Skehan P, Storeng R, Scudiero D et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990; 82: 1107-1112.
31. Abrams TJ, Lee LB, Murray LJ et al. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003; 2: 471-478.
32. Mendel DB, Laird AD, Xin X et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and plateletderived growth factor receptors: determination of a pharmacokinetic/ pharmacodynamic relationship. Clin Cancer Res 2003; 9: 327-337.
33. Murray LJ, Abrams TJ, Long KR et al. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 2003; 20: 757-766.
34. O'Farrell AM, Abrams TJ, Yuen HA et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003; 101: 3597-3605.
35. Schueneman AJ, Himmelfarb E, Geng L et al. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res 2003; 63: 4009-4016.
36. Motzer RJ, Hutson TE, Tomczak P et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27: 3584-3590.
37. Demetri GD, van Oosterom AT, Garrett CR et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006; 368: 1329-1338.
38. Stacchiotti S, Negri T, Palassini E et al. Sunitinib malate and figitumumab in solitary fibrous tumor: patterns and molecular bases of tumor response. Mol Cancer Ther 2010; 9: 1286-1297.
39. Casali PG. Do rare cancers deserve specific strategies for cancer research? Lancet Oncol 2010; 11: 506-507.